Effect of vitexin on alleviating liver inflammation in a dextran sulfate sodium (DSS)-induced colitis model - 30/11/19
pages | 7 |
Iconographies | 7 |
Vidéos | 0 |
Autres | 0 |
Graphical abstract |
Highlights |
• | Vitexin could alleviate liver injury caused by ulcerative colitis. |
• | Vitexin could inhibit the activation of TLR4/NF-κB signaling pathway. |
• | Vitexin could be a promising drug for liver injury induced by acute ulcerative colitis. |
Abstract |
As one of commonly used herbs with dual-purpose of drug and food, it has been reported that vitexin has hepatoprotective effects. However, the protective effects of vitexin on colitis-induced liver injury as well as the underlying molecular mechanisms remain unclear. The purpose of the current study was to investigate the effects and mechanisms of vitexin on liver injury induced by acute ulcerative colitis in mice. In this study, the mice model of acute ulcerative colitis was induced by 4 % dextran sodium sulphate (DSS). And then, the degree of liver injury in colitis mice was evaluated, the hepatic ALT, AST, TC and TG levels were measured by specific determination kits, the levels of TNF-α, IL-6 and IL-1β were examined by ELISA, the expressions of TLR4/NF-κB pathway related protein were detected by western blot analysis. The results indicated that hepatic histopathological changes induced by DSS were normalized by vitexin treatment, administration of vitexin decreased the liver levels of ALT and TC in mice with liver injury and reduced the release amounts of DSS-induced pro-inflammatory cytokines TNF-α, IL-6 and IL-1β. Furthermore, we found that vitexin inhibited the activation of TLR4/NF-κB signaling pathway induced by DSS. In conclusion, vitexin possess hepatoprotective activities against colitis-induced liver injury, it has potential application prospects in the treatment of liver injury induced by ulcerative colitis.
Le texte complet de cet article est disponible en PDF.Keywords : Vitexin, Ulcerative colitis, Liver injury, Inflammation
Plan
Vol 121
Article 109683- janvier 2020 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?